ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

Tune in to the ASCO in Action podcast series for analysis and commentary on cancer policy and practice issues. The podcast is available through iTunes or Google Play.

Showing results for Healthcare Reform

September 30, 2020

ASCO applauds Senators Richard Burr (R-NC) and Ben Cardin (D-MD) for introducing bipartisan legislation to expand access to clinical trials and improve the quality of cancer research. The CLINICAL TREATMENT Act (S. 4742) would require Medicaid to guarantee coverage of the routine care costs of clinical trial participation for Medicaid enrollees with a life-threatening condition.

September 29, 2020

The Association for Clinical Oncology (ASCO) submitted comments to the Food and Drug Administration (FDA) in response to its Proposed Rule – Annual Summary Reporting Requirements Under the Right to Try Act, which proposes a statutory requirement where sponsors and manufacturers must provide an annual summary of any investigational drugs supplied for use to an eligible patient.

September 22, 2020

The Association for Clinical Oncology (ASCO) held its first-ever virtual Advocacy Summit and online Week of Action September 9 – 18, 2020. The largest Advocacy Summit to date, 170  ASCO volunteer leaders and oncology care providers participated in 200 virtual meetings with Members of Congress and their staff to advocate for policies that would improve access to high-quality, equitable care for people with cancer and ensure robust funding for cancer research. Participants represented 44 different states, as well as Puerto Rico and the District of Columbia.

August 31, 2020

On September 16, the Association for Clinical Oncology (ASCO) will be hosting its first ever completely virtual Advocacy Summit. Oncology care providers from across the United States will meet with Members of Congress and their staff by phone or video to advocate for policies that will improve access to high-quality, equitable care for people with cancer and ensure robust funding for cancer research.

August 26, 2020

The Association for Clinical Oncology (ASCO) recently submitted comments to the Office of the National Coordinator for Health Information Technology (ONC) in response to its request for comments on improving patient identification and matching in the nation’s health information technology infrastructure.

July 21, 2020

The American Society of Clinical Oncology (ASCO) and Association of Community Cancer Centers (ACCC) today announced a new collaboration to foster participation in cancer treatment trials to more fully reflect the diversity of people at risk for or living with cancer.

July 21, 2020

The US Food and Drug Administration (FDA) recently finalized four new final Guidance for Industry documents for cancer clinical trial eligibility criteria that describe ways that clinical trials can safely include patients who have historically been excluded. The guidance documents complement ongoing work by ASCO and Friends of Cancer Research (Friends) to eliminate overly restrictive eligibility criteria that can exclude patients from trials without scientific or participant safety justification. Clinical trials provide patients with cancer access to promising investigational therapies – which are sometimes the only treatment option available – and advance clinical care by producing safety and efficacy data about new therapies.

June 23, 2020

On June 23, 2020, JCO: Oncology Practice published an article on rural cancer care as part of the State of Cancer Care in America series. "Closing the Rural Cancer Care Gap: Three Institutional Approaches," draws from the second event in the State of Cancer Care in America series and supporting literature to summarize the challenges to delivering high-quality care in rural communities, highlight institutional approaches to addressing these challenges, and update ASCO’s rural workforce data.

May 12, 2020

The Association for Clinical Oncology (ASCO) recently sent a letter to House and Senate leadership urging their support for policies to increase diversity in clinical trials, including the CLINICAL TREATMENT Act (H.R. 913), in a future COVID-19 response package.

April 9, 2020

The American Society of Clinical Oncology (ASCO) today released a set of recommendations to support the oncology community as health care institutions across the United States face potentially difficult decisions around the allocation of scarce health care resources during the COVID-19 pandemic. In some geographic areas, the ongoing crisis is expected to demand more resources—including ventilators, critical and intensive care beds, and medications—than the U.S. or local health care systems can supply, and institutions will need to develop allocation decision policies as they provide care for a growing number of patients.

March 17, 2020

The Association for Clinical Oncology (ASCO) recently submitted comments in response to Part II of the Centers for Medicare & Medicaid Services’ (CMS) calendar year 2021 Advance Notice of Methodological Changes for Medicare Advantage Capitation Rates and Part C and Part D Payment Policies. The advance notice proposes updates and changes to the methodologies used to pay Medicare Advantage plans, Programs of All-Inclusive Care for the Elderly organizations, and Part D sponsors.

March 3, 2020

In a letter to the Centers for Medicare & Medicaid Services (CMS), the Association for Clinical Oncology (ASCO) expressed concerns regarding two provisions in the 2021 Affordable Care Act (ACA) Notice of Benefit and Payment Parameters proposed rule. This proposal, if implemented, would update the regulatory and financial standards applied to ACA Exchanges. 

February 19, 2020

The American Society of Clinical Oncology (ASCO) today released a position statement on state drug repository programs, outlining ASCO’s support for drug repository programs solely for oral medications provided they are maintained within a closed system. The Society also makes recommendations to help ensure that these programs are implemented appropriately, with sufficient patient protections in place. 

February 18, 2020

On February 18, 106 organizations representing patients, providers, medical researchers, survivors, and families joined together to urge Congress to include the bipartisan CLINICAL TREATMENT Act (H.R. 913) in the upcoming ‘must pass’ healthcare extenders package, which is expected to pass this spring. 

February 6, 2020

The American Society of Clinical Oncology (ASCO) released a statement applauding the Centers for Medicare & Medicaid Services (CMS) for reflecting recommendations in the Society’s position statement on pharmacy benefit managers (PBMs) in the agency’s 2021 and 2022 Medicare Advantage and Part D proposed rule.  

Pages